Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.34 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 8/20 | 0.33 |
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.32 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.32 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 7/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30658427 | 0.81 | KCNH2 (0.43) | KDM4EALDH1A1HCRTR1TLR7HDAC4 | |
| SCHEMBL24120466 | 0.81 | KCNH2 (0.43) | KDM4EALDH1A1HCRTR1TLR7HDAC4 | |
| SCHEMBL19203407 | 0.80 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| SCHEMBL19203405 | 0.80 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| SCHEMBL30658431 | 0.80 | KDM4E (0.41) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| SCHEMBL19477571 | 0.78 | KDM4E (0.39) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| Hydrochloric Acid SCHEMBL30361735 | 0.77 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| Hydrochloric Acid SCHEMBL28378739 | 0.77 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| Hydrochloric Acid SCHEMBL28378737 | 0.77 | KDM4E (0.38) | KDM4EALDH1A1SMN1; SMN2PCSK9BCDIN3D | |
| SCHEMBL19477572 | 0.75 | HCRTR1 (0.34) | KDM4EALDH1A1SMN1; SMN2HCRTR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696654-B2 | Therapeutic compounds | C4X DISCOVERY LIMITED (GB) | 2020-06-30 | — | — | US | disclosed |
| US-20190040041-A1 | THERAPEUTIC COMPOUNDS | INDIVIOR UK LIMITED (GB) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696654-B2 | Therapeutic compounds | HCRTR2, HCRTR1, NPY1R | KDM4E 2777/4885ALDH1A1 1070/4885SMN1; SMN2 1337/4885 |
| US-20190040041-A1 | THERAPEUTIC COMPOUNDS | HCRTR2, HCRTR1, NPY1R | KDM4E 2777/4885ALDH1A1 1070/4885SMN1; SMN2 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.